Furthermore, enhanced cytotoxic CD8+ T-cell responses and inhibition of tumor growth have been achieved by targeting nanovaccines to tumor-draining lymph nodes rather than non-tumor draining lymph nodes, suggesting that antigen-primed but immune-suppressed lymphoid tissues can serve as ideal sites of immune activation [48]. The gene discussed is CD8A; the disease is neoplasm.